Adamis Pharmaceuticals Corp (DMK)
Company Info
US00547W3079
A3EEVQ
Aug 14, 1995
Highlights
$6.81M
-$5.78
$0.23 - $0.23
$1.50
2.36%
0.13
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
DMK
N/A
N/A
N/A
N/A
N/A
N/A
N/A
^GSPC (Benchmark)
0.52%
6.32%
-1.44%
12.25%
12.45%
14.20%
10.84%
Monthly Returns
The table below presents the monthly returns of DMK, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | -22.86% | -83.67% | -41.04% | 32.69% | 236.23% | 0.00% | -66.86% | ||||||
| 2023 | 17.65% | 10.00% | -45.45% | -33.33% | -62.68% | 15.31% | -40.66% | -43.36% | -14.81% | -26.09% | 5.88% | 29.63% | -94.12% |
| 2022 | -1.64% | 6.67% | -10.94% | -31.58% | 25.64% | 2.04% | -24.00% | -13.16% | -39.39% | -30.00% | 42.86% | -15.00% | -72.13% |
| 2021 | 134.69% | -2.61% | -16.07% | -15.96% | -12.66% | 59.42% | 7.27% | -7.63% | -11.01% | 8.25% | -21.90% | -25.61% | 24.49% |
| 2020 | -5.71% | -13.64% | -36.84% | 44.44% | -5.77% | 10.20% | 118.52% | -44.07% | 18.18% | -8.97% | -39.44% | 13.95% | -30.00% |
| 2019 | 36.44% | -3.58% | -28.72% | -2.84% | -26.34% | -13.91% | -11.54% | -18.26% | -25.53% | 15.71% | -28.40% | 20.69% | -68.89% |
| 2018 | -17.05% | -17.81% | 16.67% | 2.86% | 19.44% | -25.58% | -0.00% | -10.94% | 22.81% | -26.86% | 19.14% | -26.23% | -48.86% |
| 2017 | -1.59% | 11.29% | 23.19% | -12.94% | 4.05% | 35.06% | -11.54% | 18.48% | -4.04% | -0.57% | -26.92% | 15.79% | 39.68% |
| 2016 | -12.04% | 22.11% | 5.69% | 34.58% | 5.09% | -67.70% | 0.36% | 4.98% | 16.27% | -24.78% | 8.53% | 12.50% | -41.67% |
| 2015 | 10.53% | -5.87% | -38.63% | 9.14% | -0.70% | -1.64% | -0.24% | -12.65% | 5.74% | 11.63% | 5.32% | 18.68% | -12.48% |
| 2014 | 4.23% | -0.15% | -4.36% | -14.78% | 4.43% | -15.02% | -21.62% | 6.63% | 16.42% | 0.21% | -11.94% | 49.39% | -3.44% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of DMK is 49, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Adamis Pharmaceuticals Corp (DMK) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Adamis Pharmaceuticals Corp. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Adamis Pharmaceuticals Corp was 100.00%, occurring on Feb 15, 2024. The portfolio has not yet recovered.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -100% | Nov 23, 1999 | 6096 | Feb 15, 2024 | — | — | — |
| -73.29% | Jun 11, 1996 | 271 | Jul 7, 1997 | 95 | Nov 18, 1997 | 366 |
| -70.07% | Nov 19, 1997 | 197 | Sep 1, 1998 | 296 | Nov 3, 1999 | 493 |
| -35.19% | Aug 25, 1995 | 76 | Dec 12, 1995 | 41 | Feb 9, 1996 | 117 |
| -22.22% | Feb 12, 1996 | 27 | Mar 20, 1996 | 40 | May 16, 1996 | 67 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Adamis Pharmaceuticals Corp over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Adamis Pharmaceuticals Corp, comparing actual results with analytics estimates. The company met analyst expectations for EPS in the past quarter.
Valuation
The Valuation section provides an overview of how Adamis Pharmaceuticals Corp is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for DMK relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, DMK has a P/S ratio of 1.9. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for DMK in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, DMK has a P/B value of 7.9. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |